前列腺癌放疗:每日图像引导缩小边缘对比每周正交验证对患者报告结局的影响
一项在挪威两个放疗中心开展的开放标签3期随机试验,纳入257例中高危前列腺癌患者,随机接受每日CBCT IGRT(7 mm PTV边缘)或每周离线正交门静脉成像(15 mm PTV边缘),主要终点为放疗结束时急性直肠毒性(QUFW94直肠困扰量表)。结果显示两组主要终点无差异(1.871 vs 1.884,p=0.804),其他胃肠道、泌尿症状及健康相关生活质量亦无显著差异。
要点
- 每日CBCT IGRT缩小PTV边缘至7 mm对比每周正交验证15 mm边缘,未改善患者报告的放疗结束时急性直肠症状。
- 两组在QUFW94报告的其他胃肠道或泌尿症状及EORTC QLQ 30生活质量方面均无显著差异。
- 研究提示前列腺癌根治性放疗中,每日IGRT缩小边缘的优势未体现在患者报告副作用上。
核心结论
- 前列腺癌根治性放疗中,每日CBCT IGRT缩小PTV边缘对比每周正交离线门静脉成像标准边缘,在放疗结束时患者报告副作用方面无优势。
研究设计与样本
- 开放标签3期随机对照试验,在挪威两个放疗中心开展,纳入257例既往未治疗的组织学证实中危或高危前列腺腺癌患者。
- 患者接受3个月全雄激素阻断后随机分配至78 Gy/39次,分别接受每周离线正交门静脉成像(PTV边缘15 mm)或每日在线CBCT IGRT(PTV边缘7 mm)。
- 主要终点为放疗结束时急性直肠毒性,采用QUFW94直肠困扰量表(5个条目)评估。
主要发现
- 257例患者随机分配至每周离线门静脉成像组(n=129)或每日在线CBCT IGRT组(n=128),250例可评估患者中基线PRO完成率96%、放疗结束时97%。
- 主要终点QUFW94直肠困扰量表评分两组无差异(1.871 vs 1.884,p=0.804)。
- QUFW94报告的其他胃肠道或泌尿症状两组均无显著差异,EORTC QLQ 30生活质量分析亦无差异。
关键数值与推荐
- 放疗剂量方案为78 Gy分39次,每周离线正交门静脉成像组PTV边缘15 mm,每日在线CBCT IGRT组PTV边缘7 mm。
- 主要终点采用QUFW94直肠困扰量表(5个条目)评估放疗结束时急性直肠毒性。
临床怎么用
- 对于前列腺癌根治性放疗,每日CBCT IGRT缩小PTV边缘至7 mm未显示出患者报告副作用的改善,临床决策需综合考量其他因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel cancer drugs are subject to strict scientific evaluation of safety and efficacy and usually undergo a cost effectiveness analysis before approval for use in clinical practice. For new techniques in radiotherapy (RT) such as image-guided radiotherapy (IGRT), this is often not the case. We performed a randomized controlled trial to compare daily cone beam computer tomography (CBCT) IGRT with reduced planning target volume (PTV) margins vs weekly orthogonal portal imaging with conventional PTV margins. The primary aim of the study was to investigate the effect of two different image guidance techniques on patient reported outcome (PRO) using early side effects as proxy outcome of late rectal side effects in patients receiving curative RT for prostate cancer. METHODS: This open label, phase 3 trial conducted at two RT centers in Norway enrolled men aged 18 years or older with previously untreated histologically proven intermediate or high-risk adenocarcinoma of the prostate. Patients eligible for radical RT received it after 3 months of total androgen blockage and were randomly assigned to 78 Gy in 39 fractions guided either by weekly offline orthogonal portal imaging (15 mm margins to PTV) or by daily online CBCT IGRT (7 mm margins to PTV). Based on previous results indicating that acute rectal side effects are a valid proxy outcome for late rectal side effects, the primary outcome was acute rectal toxicity at end of RT as evaluated by rectal bother scale (five of the items from PRO's QUFW94). The RIC-trial is registered with ClinicalTrials.gov, number NCT01550237. FINDINGS: Between October 2012 and June 2015, 257 patients were randomly assigned to weekly offline portal imaging (n = 129) or daily online CBCT IGRT (n = 128). Out of 250 evaluable patients, 96% completed PROs at baseline and 97% at end of RT. Baseline analyses demonstrated balance between groups for baseline characteristics as well as for PROs. In general, patients reported a small degree of side effects at end of RT, and there was no difference between groups for primary outcome (rectal bother scale of QUFW94 1.871 vs 1.884, p = 0.804). In addition, there were no significant differences between groups for any other gastrointestinal or urinary symptom as reported by QUFW94. Health related quality of life analyses (EORTC QLQ 30) demonstrated no differences between groups. INTERPRETATION: In radical RT for prostate cancer, daily CBCT IGRT with reduced PTV margins demonstrated no advantage with respect to patient reported side effects at end of RT as compared to weekly orthogonal offline portal imaging with standard PTV margins.
引用
- Tøndel H, Lund JÅ, Lydersen S, et al. Radiotherapy for prostate cancer - Does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? Results from a randomized controlled trial. Radiother Oncol. 2018. PMID: 29398152. doi:10.1016/j.radonc.2017.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。